Journal article

Naftidrofuryl in the treatment of vascular dementia

HJ Moller, A Hartmann, C Kessler, M Rainer, T Brown, S Gamand, P Lehert

EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE | DR DIETRICH STEINKOPFF VERLAG | Published : 2001

Abstract

The design of this study was based on the European guidelines for the treatment of Alzheimer's disease. After a placebo run-in period of 4 weeks, patients with a diagnosis of vascular dementia (VaD) were randomised to receive either 400 mg naftidrofuryl/day, 600 mg naftidrofuryl/day or placebo for 6 months. The patients were assessed using the ADAS-cog, the SCAG, the NOSGER and the CGI item 2 scale. The primary analysis was undertaken on the ITT population. At the end of the study, significantly more patients in the treatment groups showed no deterioration on both ADAS-cog and SCAG scales compared with placebo (400 mg p = 0.005, 600mg p = 0.015). There were also significant differences betwe..

View full abstract